AbCellera Biologics Inc. (ABCL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q4 '20: 233.2M Q1 '21: 431.2M Q2 '21: 447.7M Q3 '21: 443.8M Q4 '21: 375.2M Q1 '22: 489.1M Q2 '22: 507.3M Q3 '22: 603.2M Q4 '22: 485.4M Q1 '23: 181M Q2 '23: 145.2M Q3 '23: 50.4M Q4 '23: 38M Q1 '24: 35.8M Q2 '24: 33.1M Q3 '24: 33M Q4 '24: 28.8M Q1 '25: 23.1M Q2 '25: 32.9M Q3 '25: 35.3M Q4 '25: 75.1M Q1 '26: 79.2M Q2 '26: 66.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '20: 156M Q1 '21: 316.2M Q2 '21: 310M Q3 '21: 283.7M Q4 '21: 204.5M Q1 '22: 271.4M Q2 '22: 270M Q3 '22: 335.8M Q4 '22: 216.5M Q1 '23: -73.3M Q2 '23: -116.3M Q3 '23: -208.9M Q4 '23: -237.2M Q1 '24: -227.2M Q2 '24: -269.3M Q3 '24: -308.1M Q4 '24: -314.8M Q1 '25: -322.5M Q2 '25: -278.7M Q3 '25: -261.3M Q4 '25: -217.1M Q1 '26: -212M Q2 '26: -225.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -90M 0 90M 180M 270M Q4 '20: 118.9M Q1 '21: 238.2M Q2 '21: 229.2M Q3 '21: 210.5M Q4 '21: 153.5M Q1 '22: 204.8M Q2 '22: 200.4M Q3 '22: 248.4M Q4 '22: 158.5M Q1 '23: -50.2M Q2 '23: -73.9M Q3 '23: -129.1M Q4 '23: -146.4M Q1 '24: -146.9M Q2 '24: -153.3M Q3 '24: -175.8M Q4 '24: -162.9M Q1 '25: -167.9M Q2 '25: -165.7M Q3 '25: -171.7M Q4 '25: -146.4M Q1 '26: -144M Q2 '26: -164.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-300M -150M 0 150M 300M 450M Q4 '20: 22.7M Q1 '21: 133M Q2 '21: 264.7M Q3 '21: 262.6M Q4 '21: 244.6M Q1 '22: 235.3M Q2 '22: 350.6M Q3 '22: 229.7M Q4 '22: 277.4M Q1 '23: 133.1M Q2 '23: -120M Q3 '23: 6.6M Q4 '23: -43.9M Q1 '24: -41.5M Q2 '24: -91.4M Q3 '24: -120.2M Q4 '24: -108.6M Q1 '25: -78.4M Q2 '25: -80.8M Q3 '25: -104.6M Q4 '25: -131.3M Q1 '26: -153.3M Q2 '26: -94.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-200M -100M 0 100M 200M 300M Q4 '20: 13M Q1 '21: 120.3M Q2 '21: 218.9M Q3 '21: 212.1M Q4 '21: 186.1M Q1 '22: 166M Q2 '22: 286.8M Q3 '22: 162M Q4 '22: 206.7M Q1 '23: 61.9M Q2 '23: -187.1M Q3 '23: -68.2M Q4 '23: -120.8M Q1 '24: -127.6M Q2 '24: -170.4M Q3 '24: -197.4M Q4 '24: -187M Q1 '25: -143.3M Q2 '25: -139M Q3 '25: -153.1M Q4 '25: -174.1M Q1 '26: -189.2M Q2 '26: -119.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '20: 151.9M Q2 '20: 260.8M Q3 '20: 153M Q1 '21: 320.3M Q2 '21: 272.2M Q3 '21: 278.9M Q1 '22: 311.5M Q2 '22: 284.7M Q3 '22: 315.8M Q1 '23: 287.8M Q2 '23: 288.9M Q3 '23: 289.5M Q1 '24: 292.7M Q2 '24: 294.2M Q3 '24: 294.9M Q1 '25: 297.7M Q2 '25: 298.5M Q3 '25: 298.9M Q1 '26: 303.1M Q2 '26: 305.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q4 '20: 0.44 Q1 '21: 0.82 Q2 '21: 0.78 Q3 '21: 0.72 Q4 '21: 0.47 Q1 '22: 0.64 Q2 '22: 0.63 Q3 '22: 0.79 Q4 '22: 0.50 Q1 '23: -0.18 Q2 '23: -0.27 Q3 '23: -0.45 Q4 '23: -0.52 Q1 '24: -0.52 Q2 '24: -0.54 Q3 '24: -0.61 Q4 '24: -0.55 Q1 '25: -0.56 Q2 '25: -0.55 Q3 '25: -0.57 Q4 '25: -0.49 Q1 '26: -0.48 Q2 '26: -0.54 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.